SanDisk Corporation (NASDAQ:SNDK) said on its conference call Thursday night it expects Q4 revenue of $1.80 to $1.85 billion, vs. the analyst consensus of $1.87 billion on Capital IQ. SanDisk Corporation (NASDAQ:SNDK) also noted that for 2015, it plans to increase its supply bit growth from less than 25% this year to a range of 30% to 40%. Given the lean level of inventory it will have at the end of 2014, its 2015 revenue bit growth will likely need to be at the low end of that range. For Q4, it expects its non-GAAP gross margin to be between 47% and 49%.It also said, "We expect Q4 non-GAAP operating expenses of $380 million to $390 million, reflecting a full quarter of Fusion-io-related expenses and inclusive of restructuring expenses of approximately $15 million. Q4 non-GAAP other income is forecasted at approximately $3 million, and we expect our non-GAAP tax rate to be equal to the Q3 rate of 31.2%. We expect our Q4 non-GAAP diluted share count to come down to approximately 228 million, reflecting continued share repurchases."GlobeImmune Inc (NASDAQ:GBIM) said Friday it released results from a Phase 1 study of its drug GI-6301, to treat the cancer chordoma, or bone cancer, at the ongoing Connective Tissue Oncology Society meeting in Germany. The GI-6301 drug, aka Tarmogen, targets bone cancers that typically afflict the spine and base of skull. GlobeImmune Inc (NASDAQ:GBIM) reported its drug is generally well tolerated, immunogenic, and showed evidence of clinical activity in a trial of 11 patients. Presently,chordoma is treated by surgery and radiation, often in multiple rounds. GBIM said the trial results provided a rationale for phase 2 trials.Honeywell International Inc. (NYSE:HON) a aerospace and security technologies company, said Q3 earnings rose 14% to $1.43 per share, exceeding the $1.41 average estimate from analysts polled by Capital IQ. Sales rose 5% to $10.1 billion, coming in slightly ahead of the $10.0 billion consensus estimate. Reported net income rose to $1.17 billion or $1.47 per diluted share from $990 million or $1.24 the year earlier. Honeywell meanwhile said it now expects FY EPS of $5.50 to $5.55, up from the previous guidance range between $5.45 and $5.55 and compared to the $5.54 average estimate. The sales guidance is now between $40.3 billion and $40.4 billion compared to the previous guidance of $40.2 billion to $40.4 billion and in line with the $40.38 billion consensus estimate."Looking ahead to 2015, we're once again planning for a slow growth macro environment, but expect to continue delivering strong earnings growth," CEO Dave Cote said in a statement. "We're confident that Honeywell will continue to outperform now and over the long-term driven by a relentless focus on new products and technologies, continued penetration of high-growth regions, and sustained implementation of our key process initiatives." Honeywell International Inc. (NYSE:HON) is trading in the lower half of the 52-week range between $82.89 and $98.09.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
